Home / Company

Company

4,3 Millions d’Euros de levés pour initier la Phase II

Après le succès de sa Phase I, Invectys lève 4.3 Millions d’Euros permettant la rentrée en Phase II de ses deux vaccins anticancéreux   Paris, le 12…

Read more

Invectys presents its INVAC-1 therapeutic vaccine Phase...

Presentation of the Invectys clinical trial results on cancer patients at the most important worldwide oncology meeting taking place this year in Chicago, USA Paris,…

Read more

Invectys at ASCO 2017 in Chicago : Clinical Oncology

Invectys attend ASCO 2017 meeting in Chicago  Invectys will be at the Annual Meeting is organized by American Society Of Clinical Oncology (ASCO). This meeting…

Read more

Mission and vision

Invectys Mission and vision Invectys focuses on the development of innovative anti-cancer therapeutic approaches in immunotherapy. It is backed by French and international…

Read more

Invectys’ achievements

Raised over 17 Millions € Moved 2 products into phase I clinical trials 10 patents filed Preparing 2 phase II clinical trials in the USA and in France Has an exciting…

Read more

About Invectys

Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. …

Read more

Scientific and Clinical Board

Invectys’ Scientific and Clinical Board is made up of top specialists and key opinion leaders around the world Professor Michael Keating MD, Anderson Cancer…

Read more

Management team

​ Pierre Langlade Demoyen CEO MD & PhD in immunology. A laboratory head at the Institut Pasteur in Paris, Pierre Langlade Demoyen has published 70 scientific…

Read more